KR101585280B1 - 고형 의약 제제 - Google Patents
고형 의약 제제 Download PDFInfo
- Publication number
- KR101585280B1 KR101585280B1 KR1020107028058A KR20107028058A KR101585280B1 KR 101585280 B1 KR101585280 B1 KR 101585280B1 KR 1020107028058 A KR1020107028058 A KR 1020107028058A KR 20107028058 A KR20107028058 A KR 20107028058A KR 101585280 B1 KR101585280 B1 KR 101585280B1
- Authority
- KR
- South Korea
- Prior art keywords
- solid pharmaceutical
- granules
- starch
- pharmaceutical preparation
- enteric
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
[도 2} 실시예 2와 대조예 2의 용출 거동을 나타낸다.
[도 3] 실시예 3과 대조예 3의 용출 거동을 나타낸다.
[도 4] 실시예 4와 대조예 4의 용출 거동을 나타낸다.
[도 5] 실시예 5와 대조예 5의 용출 거동을 나타낸다.
[도 6] 실시예 6과 대조예 6의 용출 거동을 나타낸다.
[도 7] 실시예 4 내지 6과 대조예 7을 투여한 경우의 혈장 중 실로스타졸 농도의 경시 변화를 나타낸다(n=7, 평균값±표준편차).
Claims (26)
- (a) 실로스타졸, (b) 제제의 총 중량 기준으로 10 내지 90 중량%의 α화 전분(pre-gelatinized starch), (c) 1종 이상의 장용성 성분 및 (d) 유기산을 함유하는 고형 의약 제제.
- 삭제
- 삭제
- 제1항에 있어서, 1종 이상의 장용성 성분이 히드록시프로필 메틸셀룰로오스 아세테이트 숙시네이트, 히드록시프로필 메틸셀룰로오스 프탈레이트, 카르복시메틸에틸셀룰로오스, 메타크릴산 공중합체 L 및 메타크릴산 공중합체 S로 구성된 군으로부터 선택되는 것인 고형 의약 제제.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 제1항에 있어서, 유기산이 0.5 중량% 내지 5 중량%로 함유되는 고형 의약 제제.
- 제1항에 있어서, 유기산이 시트르산인 고형 의약 제제.
- 제13항에 있어서, 장용성 성분이 메타크릴산 공중합체 S를 포함하는 고형 의약 제제.
- 제1항에 있어서, α화 전분이 α화 옥수수 전분인 고형 의약 제제.
- 제1항에 있어서, 하기 공정 (i) 및 (ii)에 의해 제조되는 고형 의약 제제:
(i) 실로스타졸, 전분, 1종 이상의 장용성 성분 및 유기산을 혼합하여 원료 조성물을 제조하는 공정, 및
(ii) 원료 조성물 중의 전분을 α화하는 공정. - 제16항에 있어서, (i)에서의 전분이, 전분 및 부분 α화 전분 중 하나이거나, 또는 전분, 부분 α화 전분 및 α화 전분으로 구성된 군으로부터 선택된 2종 또는 3종의 혼합물인 것인 고형 의약 제제.
- 제1항에 있어서, 형상이 입상인 고형 의약 제제.
- 제1항에 있어서, 형상이 과립 또는 세립인 고형 의약 제제.
- 제19항에 있어서, 압출 조립법에 의해 제조된 고형 의약 제제.
- 형상이 입상, 과립 또는 세립, 또는 압출 조립법에 의해 제조된 과립 또는 세립인 제1항에 기재된 고형 의약 제제를 1종 이상 포함하는 캡슐제.
- 형상이 입상, 과립 또는 세립, 또는 압출 조립법에 의해 제조된 과립 또는 세립인 제1항에 기재된 고형 의약 제제를 1종 이상 포함하는 정제.
- 제조 공정 중에 가열함으로써 전분을 α화하는, 제1항에 기재된 고형 의약 제제의 제조 방법.
- 제23항에 있어서, 가열이 가습을 수반하는 방법.
- 제23항 또는 제24항에 기재된 방법에 의해 제조된 고형 의약 제제.
- 실로스타졸을 함유하는 속방성의 과립 또는 세립과, 형상이 입상, 과립 또는 세립, 또는 압출 조립법에 의해 제조된 과립 또는 세립인 제1항에 기재된 고형 의약 제제를 1종 이상 충전한 캡슐제.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008128259 | 2008-05-15 | ||
JPJP-P-2008-128259 | 2008-05-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20110007255A KR20110007255A (ko) | 2011-01-21 |
KR101585280B1 true KR101585280B1 (ko) | 2016-01-13 |
Family
ID=40847022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020107028058A KR101585280B1 (ko) | 2008-05-15 | 2009-05-14 | 고형 의약 제제 |
Country Status (32)
Country | Link |
---|---|
US (1) | US20110091535A1 (ko) |
EP (1) | EP2273981B1 (ko) |
JP (1) | JP5552434B2 (ko) |
KR (1) | KR101585280B1 (ko) |
CN (2) | CN102119024A (ko) |
AR (1) | AR071706A1 (ko) |
AU (1) | AU2009247156B2 (ko) |
BR (1) | BRPI0912656A2 (ko) |
CA (1) | CA2722244C (ko) |
CL (1) | CL2009001183A1 (ko) |
CO (1) | CO6321223A2 (ko) |
CY (1) | CY1115955T1 (ko) |
DK (1) | DK2273981T3 (ko) |
EA (1) | EA022712B1 (ko) |
EC (1) | ECSP10010683A (ko) |
ES (1) | ES2524261T3 (ko) |
HK (1) | HK1149497A1 (ko) |
HR (1) | HRP20141134T1 (ko) |
IL (1) | IL208788A (ko) |
MX (1) | MX2010012432A (ko) |
MY (1) | MY153109A (ko) |
NZ (1) | NZ588794A (ko) |
PE (2) | PE20091900A1 (ko) |
PL (1) | PL2273981T3 (ko) |
PT (1) | PT2273981E (ko) |
RS (1) | RS53775B1 (ko) |
SG (1) | SG190643A1 (ko) |
SI (1) | SI2273981T1 (ko) |
TW (1) | TWI501789B (ko) |
UA (1) | UA102547C2 (ko) |
WO (1) | WO2009139504A2 (ko) |
ZA (1) | ZA201008115B (ko) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101282847B1 (ko) * | 2011-07-27 | 2013-07-05 | 조선대학교산학협력단 | 실로스타졸을 함유하는 고체분산체 및 이를 포함하는 약학 조성물 |
TWI615157B (zh) * | 2013-02-06 | 2018-02-21 | 大塚製藥股份有限公司 | 包括不定形西洛他唑的固體分散劑 |
CN103920156B (zh) * | 2014-04-04 | 2016-06-01 | 成都科特包衣技术有限公司 | 一种口服给药肠道定位释药薄膜包衣预混辅料及其制备方法 |
CN106511313B (zh) * | 2016-10-21 | 2019-06-07 | 浙江为康制药有限公司 | 西洛他唑缓释胶囊组合物及其制备方法 |
EP3409294A1 (en) | 2017-06-01 | 2018-12-05 | Przedsiebiorstwo Farmaceutyczne Lek-Am Sp Z O. O. | Tablets containing cilostazol of specific particle size distribution |
JPWO2020218517A1 (ko) * | 2019-04-25 | 2020-10-29 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007105229A1 (en) * | 2006-03-14 | 2007-09-20 | Panacea Biotec Ltd. | Controlled release pharmaceutical composition and process thereof |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT8920486A0 (it) * | 1989-05-12 | 1989-05-12 | Isf Spa | Composizioni farmaceutiche. |
US5914132A (en) * | 1993-02-26 | 1999-06-22 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
US5843479A (en) * | 1993-02-26 | 1998-12-01 | The Procter & Gamble Company | Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery |
EG23951A (en) * | 1999-03-25 | 2008-01-29 | Otsuka Pharma Co Ltd | Cilostazol preparation |
JP4641696B2 (ja) * | 1999-09-30 | 2011-03-02 | 大塚製薬株式会社 | 消化管下部溶解性コーティング製剤 |
JP4637338B2 (ja) * | 2000-09-22 | 2011-02-23 | 大塚製薬株式会社 | シロスタゾール有核錠 |
JP2002193792A (ja) * | 2000-12-25 | 2002-07-10 | Lion Corp | フィルムコーティング錠剤及びエロージョン防止組成物 |
AU2003301762B2 (en) * | 2002-10-25 | 2006-02-09 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
US7670627B2 (en) * | 2002-12-09 | 2010-03-02 | Salvona Ip Llc | pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients |
BR0317593A (pt) * | 2002-12-20 | 2005-11-22 | Pfizer Prod Inc | Formas de dosagem compreendendo um inibidor de cetp e um inibidor de hmg-coa reductase |
WO2005023225A1 (en) * | 2003-09-05 | 2005-03-17 | Ranbaxy Laboratories Limited | Cilostazol adsorbate |
US20050255155A1 (en) * | 2004-05-11 | 2005-11-17 | Glenmark Pharmaceuticals Limited | Modified release cilostazol compositions |
JP5112619B2 (ja) * | 2004-05-20 | 2013-01-09 | 大塚製薬株式会社 | 固形医薬製剤 |
TWI338583B (en) * | 2004-05-20 | 2011-03-11 | Otsuka Pharma Co Ltd | Solid pharmaceutical formulation |
EP1945189A4 (en) * | 2005-11-03 | 2012-08-15 | Sun Pharmaceutical Ind Ltd | COATED TABLETS WITH EXTENDED MAGNETIC RETENTION |
KR100888131B1 (ko) * | 2006-10-10 | 2009-03-11 | 한올제약주식회사 | 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제 |
WO2008054121A1 (en) * | 2006-10-30 | 2008-05-08 | Hanall Pharmaceutical Company. Ltd | Controlled release pharmaceutical composition containing thiazides and angiotensin-ii-receptor blockers |
SI2180882T1 (sl) * | 2007-10-19 | 2013-05-31 | Otsuka Pharmaceutical Co., Ltd. | Trdni matriksni farmacevtski pripravek |
WO2009118764A1 (en) * | 2008-03-28 | 2009-10-01 | Panacea Biotec Limited | Pharmaceutical composition comprising diclofenac and paracetamol |
-
2009
- 2009-05-11 AR ARP090101693A patent/AR071706A1/es unknown
- 2009-05-12 PE PE2009000651A patent/PE20091900A1/es not_active Application Discontinuation
- 2009-05-12 PE PE2014000196A patent/PE20140962A1/es not_active Application Discontinuation
- 2009-05-14 MY MYPI20104928 patent/MY153109A/en unknown
- 2009-05-14 US US12/992,187 patent/US20110091535A1/en not_active Abandoned
- 2009-05-14 CL CL2009001183A patent/CL2009001183A1/es unknown
- 2009-05-14 BR BRPI0912656A patent/BRPI0912656A2/pt not_active IP Right Cessation
- 2009-05-14 RS RS20150078A patent/RS53775B1/en unknown
- 2009-05-14 PL PL09746710T patent/PL2273981T3/pl unknown
- 2009-05-14 CA CA2722244A patent/CA2722244C/en not_active Expired - Fee Related
- 2009-05-14 UA UAA201015072A patent/UA102547C2/uk unknown
- 2009-05-14 EP EP09746710.4A patent/EP2273981B1/en active Active
- 2009-05-14 PT PT97467104T patent/PT2273981E/pt unknown
- 2009-05-14 AU AU2009247156A patent/AU2009247156B2/en not_active Ceased
- 2009-05-14 KR KR1020107028058A patent/KR101585280B1/ko active IP Right Grant
- 2009-05-14 WO PCT/JP2009/059300 patent/WO2009139504A2/en active Application Filing
- 2009-05-14 CN CN2009801173931A patent/CN102119024A/zh active Pending
- 2009-05-14 DK DK09746710.4T patent/DK2273981T3/en active
- 2009-05-14 TW TW098115963A patent/TWI501789B/zh active
- 2009-05-14 ES ES09746710.4T patent/ES2524261T3/es active Active
- 2009-05-14 CN CN201510411765.9A patent/CN104971037A/zh active Pending
- 2009-05-14 JP JP2010545310A patent/JP5552434B2/ja not_active Expired - Fee Related
- 2009-05-14 SG SG2013035688A patent/SG190643A1/en unknown
- 2009-05-14 EA EA201071309A patent/EA022712B1/ru not_active IP Right Cessation
- 2009-05-14 NZ NZ588794A patent/NZ588794A/en not_active IP Right Cessation
- 2009-05-14 SI SI200931076T patent/SI2273981T1/sl unknown
- 2009-05-14 MX MX2010012432A patent/MX2010012432A/es active IP Right Grant
-
2010
- 2010-10-18 IL IL208788A patent/IL208788A/en not_active IP Right Cessation
- 2010-11-12 ZA ZA2010/08115A patent/ZA201008115B/en unknown
- 2010-11-19 CO CO10145075A patent/CO6321223A2/es not_active Application Discontinuation
- 2010-12-15 EC EC2010010683A patent/ECSP10010683A/es unknown
-
2011
- 2011-04-14 HK HK11103775.2A patent/HK1149497A1/xx not_active IP Right Cessation
-
2014
- 2014-11-24 HR HRP20141134AT patent/HRP20141134T1/hr unknown
-
2015
- 2015-01-28 CY CY20151100087T patent/CY1115955T1/el unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007105229A1 (en) * | 2006-03-14 | 2007-09-20 | Panacea Biotec Ltd. | Controlled release pharmaceutical composition and process thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2007010889A (es) | Formulaciones farmaceuticas gastrorresistentes que contienen rifaximina. | |
JPS5989615A (ja) | モピダモ−ル製剤 | |
KR101585280B1 (ko) | 고형 의약 제제 | |
WO2017018473A1 (ja) | 錠剤 | |
KR101302810B1 (ko) | 고형 의약 제제 | |
JP5112619B2 (ja) | 固形医薬製剤 | |
US20190125792A1 (en) | Pharmaceutical compositions comprising ferric citrate and methods for the production thereof | |
EP2175855B1 (en) | Stable pharmaceutical composition of a water-soluble vinorelbine salt | |
JP7424992B2 (ja) | コーティング方法 | |
TW202313072A (zh) | 檸檬酸鐵之兒科調配物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2016100003182; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161012 Effective date: 20170131 |
|
J206 | Request for trial to confirm the scope of a patent right | ||
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2018100000353; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20180205 Effective date: 20181211 |
|
J206 | Request for trial to confirm the scope of a patent right | ||
FPAY | Annual fee payment |
Payment date: 20181226 Year of fee payment: 4 |
|
J206 | Request for trial to confirm the scope of a patent right | ||
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2018100004160; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20181214 Effective date: 20190410 |
|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2019100001116; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20190408 Effective date: 20190528 |
|
FPAY | Annual fee payment |
Payment date: 20191217 Year of fee payment: 5 |